AN2 Therapeutics, Inc. (ANTX)
3.61
+0.47
(+14.97%)
USD |
NASDAQ |
Apr 17, 16:00
3.75
+0.14
(+3.88%)
Pre-Market: 08:30
AN2 Therapeutics SG&A Expense (Quarterly) : 2.437M for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Relmada Therapeutics, Inc. | 12.26M |
| ACADIA Pharmaceuticals, Inc. | 155.62M |
| Alnylam Pharmaceuticals, Inc. | 325.37M |
| Savara, Inc. | 12.53M |
| BioMarin Pharmaceutical, Inc. | 446.21M |